Reporting of adverse events ONLY

Patients should always seek the advice of a doctor or pharmacist in case of adverse events.

If you wish to report an adverse event to ELC Group s.r.o., please find the contact information below:

00420 224 910 672

(from 09.00-17.30 CET)

00420 723 694 460

(non-stop 24/7)

To contact us about any other issue please call:

+420 22 491 0000or our regional offices.

Hlášení nežádoucích príhod

Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod.

Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:

00420 224 910 672

(09.00-17.30 CET)

00420 723 694 460

(non-stop 24/7)

Pro záležitosti, které se netýkaji farmakovigilance, kontaktujte prosím recepci:

+420 22 491 0000 nebo naše další pobočky.

ELC Group

Your global pharma regulatory partner

ELC Group is a fully-fledged global regulatory partner, working with major pharmaceutical stakeholders for over a decade. From the development stage through to the implementation of clinical trials, completion of product registration, and successful marketing of the product, ELC Group aligns itself as a strategic partner to help pharmaceutical companies achieve their goals.

850+
clients
11,000
projects completed
60+
countries
‘ELC will always “go the extra mile” to look into complicated issues and try to find new ways of approaching different matters with the agencies.’

Sadiq Basha

Head-Regulatory Affairs, Strides Arcolab International Limited, UK

‘We have partnered with ELC Group for a number of years now and have always found them extremely easy to work with. They are flexible and knowledgeable in their approach and projects are delivered on time and within budget.’

Andrew Macaulay

President-Europe, Famy Care, India

‘ELC Group proved to be a proactive partner and its expert team’s experience has proven to be useful, especially when it comes to regulatory intelligence and agency communication.’

Maria Niktari

Business Development Director, Pharmanel, Greece

‘The transition of PV activities, including the EU QPPV service from a UK-based PV service provider to ELC was very smooth and professional. We have received many positive comments internally, regarding the timelines and quality of the services. We consider the ELC Group as a competent and reliable pharmacovigilance partner for the PV services.’

Komal Patel

Medreich PLC, UK